Complementary technology to augment MDS Analytical Technologies' cellular
SUNNYVALE, CA, June 27 /PRNewswire-FirstCall/ - MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life sciences research, today announced it has acquired California-based Blueshift Biotechnologies (Sunnyvale, CA) for $13 million. The acquisition of Blueshift Biotechnologies, a developer of screening platforms for life sciences research and maker of the IsoCyte(TM) benchtop laser scanning cytometer, expands MDS Analytical Technologies' capabilities in cellular analysis, and further strengthens the company's global sales and service offering.
High Content Screening (HCS) and High Content Analysis (HCA) are growing trends in both pharmaceutical drug screening and life sciences research. MDS Analytical Technologies' cellular imaging product line now includes imaging systems and software that provide life sciences and drug discovery researchers with a more complete solution to conduct HCS and HCA. Cellular imaging provides intracellular information on compound effects for a large variety of cellular processes. Blueshift Biotechnologies' IsoCyte(TM) instrument conducts rapid image analysis of large populations of cells in a microtiter plate whole-well format. Whole-well, rapid cellular analysis enables a cost-effective solution for the adoption of HCS and HCA into high throughput screening environments.
"This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high throughput screening rates," said Andy Boorn, president of MDS Analytical Technologies. "There are currently fourteen IsoCyte instruments installed at academic, biotech and pharmaceutical companies in North America. With our extensive global sales force, we have the ability to bring this novel product to a wider global market."
"We are very excited about this opportunity for Blueshift Biotechnologies to merge into a world-class company like MDS Analytical Technologies," stated Evan Cromwell, president of Blueshift Biotechnologies. "The breadth and strength of its sales and marketing efforts mean that we will be able to increase awareness of this unique high-throughput imaging tool in new markets."
About MDS Analytical Technologies
MDS Analytical Technologies is a newly established MDS Inc. business unit and is a world-class organization comprised of two main lines of business. The Sciex product portfolio offers proven market leadership in mass spectrometry through its joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Applied Biosystems, a business of Applera Corporation, and PerkinElmer Inc. Molecular Devices' product portfolio is the gold standard in high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Find out more at http://www.moleculardevices.com or http://www.mdssciex.com.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc. has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
|SOURCE MDS Analytical Technologies|
Copyright©2008 PR Newswire.
All rights reserved